The other thing worth setting expectations on: outcomes vary
Efficacy was evaluated in CADENZA (NCT03386513), a multicenter, open-label, single-arm clinical trial that included adult patients with treatment-nave BPDCN (n = 33) or relapsed or refractory BPDCN (n = 51) without evidence of active central nervous system disease
received funding from the internal doctoral program ELAN
10.1007/s10517-017-3876-x [DOI] [PubMed] [Google Scholar] Khavinson V, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Caputi S, Sinjari B (2020) AEDG peptide (epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism
Delivery heterogeneity blocks generalization
Treatment of pelvic pain associated with endometriosis: A committee opinion